Stock market news that you should not miss today 25th Jan 2021

Here is the important stock market news to watch out for today.

  • Markets to open on a positive note; support @14,250, resistance at 14,650.
  • FIIs sold shares worth Rs635.69cr (cash), sold Rs1290.35cr in index futures.
  • US markets closed mixed on Friday. Asian markets opened mixed.
  • Brent crude was 0.29% lower at $55.25 per barrel.
  • Tata Motors increases passenger vehicle prices. Confirms price protection for customers who have booked vehicles on or before January 21.
  • Tata Power bagged an EPC order worth Rs1,200cr from NTPC for setting up of 320MW ground mounted Solar PV project.
  • Yes, Bank witnessed a profit of Rs150.7cr in Q3FY21 against a loss of Rs18,560cr in Q3FY20. Net interest income jumped to Rs2,560.4cr from Rs1,064.7cr yoy.
  • Reliance Industries posted a consolidated profit of Rs14,894cr in Q3FY21 against Rs10,602cr in Q2FY21; revenue increased to Rs1,23,997cr from Rs1,16,195cr qoq.
  • Grasim Industries to enter paints business and will invest Rs5,000cr over the next three years.
  • UltraTech Cement reported a consolidated profit of Rs1,584cr in Q3FY21 against Rs711cr, and revenue jumped to Rs12,254.1cr from Rs10,439.3cr yoy.
  • DHFL administrator informed that committee of creditors declare Piramal Enterprises as successful resolution applicant.
  • Rossari Biotech: PAT stood at Rs21.6cr as against Rs18.3cr, higher by 18.0%.
  • Salasar Techno Engineering Limited, emerged as the lowest bidder and secured L-1 in three tenders with an amount of Rs71.74cr.
  • DCB Bank: The Bank’s Profit After Tax was at Rs96cr. In Q3FY21 as against Rs97cr in Q3FY20.
  • Birla Corporation Limited’s December quarter net profit jumped 82.l % yoy to Rs148.42cr on the back of a 3.2% growth in sales by volume, aggressive cost rationalization and higher sales of premium products.
  • Oberoi Realty: The Consolidated Profit After Tax was Rs286.43cr for Q3FY21 as against Rs148.08crfor Q3FY20 and Rs454.07cr for 9MFY21 as against Rs438.43cr for 9MFY20.
  • Zydus Cadila receives final approval from USFDA for Liothyronine Sodium Tablets.